Piper Sandler analyst Matt O’Brien raised the firm’s price target on Kestra Medical (KMTS) to $30 from $27 and keeps an Overweight rating on the shares. The firm notes the company reported strong, full fiscal Q2 results, with almost a 10% beat on the top-line. Gross margin was impressive and adjusted EBITDA loss came in better than expected. Piper views the outlook and a rapidly improving profitability profile as extremely compelling and strongly encourages investors to buy the stock.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical Technologies: Strong Financial Performance and Market Leadership Drive Buy Rating
- Closing Bell Movers: Broadcom down 5%, Lululemon gains 10%
- Kestra Medical reports Q2 EPS (64c), consensus (57c)
- Kestra Medical raises FY26 revenue view to $91M from $88M, consensus $88.02M
- Kestra Medical Technologies Ltd. (KMTS) Q2 Earnings Cheat Sheet